Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics Inc (DE:38I)
:38I
38I Stock Chart & Stats
Day’s Range― - ―
52-Week Range€6.64 - €25.23
Previous CloseN/A
Volume0.00
Average Volume (3M)283.00
Market Cap
€681.77M
Enterprise Value€796.31M
Total Cash (Recent Filing)-$9.85M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.23
Next Earnings
May 01, 2025EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.85
Shares Outstanding103,517,460
10 Day Avg. Volume181
30 Day Avg. Volume283
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)16.10
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit13.76
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
€33.40Price Target Upside341.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
---
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalIntellia's CRISPR-based TTR silencing therapy nexiguran-ziclumeran was granted regenerative medicine advanced therapy (RMAT) designation by the FDA for the treatment of ATTR-cardiomyopathy and ATTR-polyneuropathy.
Strategic InitiativesNTLA announced a strategic reorganization and anticipated milestones ahead of its sell-side analyst call.
Therapeutic EfficacyIn a Phase I trial, nex-z elicited an 89% reduction in TTR over a 28-day span, which is competitive with vutrisiran’s 70% TTR reduction over a 45-day span.
Bears Say
Commercial OutlookThe commercial outlook for nex-z after approval is uncertain due to competitive threats.
CompetitionCompetition in the ATTR-CM space is increasing due to aggressive development plans from competitors like Alnylam.
Financial PressureNTLA has been under significant pressure mainly due to a financing overhang and concerns around gene editing commercial viability.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.59% Insiders
20.66%
Mutual Funds
34.56% Other Institutional Investors
13.18% Public Companies and
Individual Investors
38I FAQ
What was Intellia Therapeutics Inc’s price range in the past 12 months?
Intellia Therapeutics Inc lowest stock price was €6.64 and its highest was €25.23 in the past 12 months.
What is Intellia Therapeutics Inc’s market cap?
Intellia Therapeutics Inc’s market cap is €681.77M.
When is Intellia Therapeutics Inc’s upcoming earnings report date?
Intellia Therapeutics Inc’s upcoming earnings report date is May 01, 2025 which is in 29 days.
How were Intellia Therapeutics Inc’s earnings last quarter?
Intellia Therapeutics Inc released its earnings results on Feb 27, 2025. The company reported -€1.176 earnings per share for the quarter, beating the consensus estimate of -€1.232 by €0.056.
Is Intellia Therapeutics Inc overvalued?
According to Wall Street analysts Intellia Therapeutics Inc’s price is currently Undervalued.
Does Intellia Therapeutics Inc pay dividends?
Intellia Therapeutics Inc does not currently pay dividends.
What is Intellia Therapeutics Inc’s EPS estimate?
Intellia Therapeutics Inc’s EPS estimate is -1.18.
How many shares outstanding does Intellia Therapeutics Inc have?
Intellia Therapeutics Inc has 103,517,460 shares outstanding.
What happened to Intellia Therapeutics Inc’s price movement after its last earnings report?
Intellia Therapeutics Inc reported an EPS of -€1.176 in its last earnings report, beating expectations of -€1.232. Following the earnings report the stock price went up 6.055%.
Which hedge fund is a major shareholder of Intellia Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:38I
---
Intellia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€33.40 (341.83% Upside)
€33.40 (341.83% Upside)
Blogger Sentiment
Bullish
DE:38I Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $824.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.55%
12-Months-Change
Fundamentals
Return on Equity
-54.00%
Trailing 12-Months
Asset Growth
-8.45%
Trailing 12-Months
Company Description
Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
---
38I Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Intellia Therapeutics reported strong progress in its clinical pipeline, particularly with Phase III enrollment for HAE and ATTR amyloidosis, and demonstrated a solid financial position to support ongoing operations. However, the company faced increased operating expenses and restructuring challenges, including program discontinuation and workforce reductions.Read More>---
38I Revenue Breakdown
100.00% Collaboration revenue
---
38I Stock 12 Month Forecast
Average Price Target
€33.40
▲(341.83% Upside)
Technical Analysis
Arcturus Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Verve Therapeutics
―
Best Analysts Covering 38I
1 Year
1 Year Success Rate
13/38 ratings generated profit
1 Year Average Return
+83.67%
reiterated a buy rating 5 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 34.21% of your transactions generating a profit, with an average return of +83.67% per trade.
---